Clinical Trial Update: PK of NRL972 in Patients with Nonalcoholic Steatohepatitis (NASH) and Non-Alcoholic Fatty Liver Disease (NAFLD) [Phase 2]

View source ↗

Summary

Phase 2 study assessing the pharmacokinetics of NRL972 in patients with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonalcoholic Fatty Liver Disease
• Nonalcoholic Steatohepatitis

Drugs mentioned

• NRL972 (NRL972)

Snippet

Sponsor: Norgine | Conditions: Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis | Phase 2 | Status: COMPLETED